Difference between revisions of "Drug toxicity"
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
This article covers a few of the distinctive histomorphologic pattern and links to other articles that deal with specific organ systems. | This article covers a few of the distinctive histomorphologic pattern and links to other articles that deal with specific organ systems. | ||
=Liver drug toxicity= | |||
*[[Drug-induced liver disease]]. | |||
=Luminal gastrointestinal pathology= | |||
==Sodium polystyrene sulfonate== | ==Sodium polystyrene sulfonate== | ||
:[[AKA]] ''Kayexalate'' (trade name). | :[[AKA]] ''Kayexalate'' (trade name). | ||
| Line 20: | Line 24: | ||
{{Main|Proton pump inhibitor effect}} | {{Main|Proton pump inhibitor effect}} | ||
=See also= | |||
*[[Minocycline associated thyroid pigmentation]]. | *[[Minocycline associated thyroid pigmentation]]. | ||
*[[Spironolactone bodies]]. | *[[Spironolactone bodies]]. | ||
=References= | |||
{{Reflist|1}} | {{Reflist|1}} | ||
[[Category:Stuff]] | [[Category:Stuff]] | ||